Findings

What do systematic reviews say?

3 questions · 3 findings · 1 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 0 · 0%Low 2 · 66.7%Moderate 1 · 33.3%High 0 · 0%

Antibody vs other antibody (stratified by antibody type)

Failure of acute rejection reversal · kidney transplant recipients: steroid‐resistant rejection episodes

Antibody showed no clear difference in failure of acute rejection reversal compared with other antibody (stratified by antibody type) (low certainty).

1 finding from 1 review

Polyclonal and monoclonal antibodies for treating acute rejection episodes in kidney transplant recipients 2017 · Cochrane Headline outcomes only
RR 1.07 [0.63, 1.81]
5 studies · 244 participants
Low

Antibody (T cell) vs steroids

Failure of acute rejection reversal · kidney transplant recipients: first rejection episode

Antibody (T cell) probably leads to lower failure of reversal of acute rejection compared with steroid (stratified by antibody type) (moderate certainty).

1 finding from 1 review

Polyclonal and monoclonal antibodies for treating acute rejection episodes in kidney transplant recipients 2017 · Cochrane Headline outcomes only
RR 0.5 [0.3, 0.82]
6 studies · 405 participants
Moderate

Antibody (T cell) + steroid vs steroids

Failure of acute rejection reversal · kidney transplant recipients: first rejection episode

Antibody (T cell) + steroid showed no clear difference in failure of reversal of acute rejection episode compared with steroid alone (low certainty).

1 finding from 1 review

Polyclonal and monoclonal antibodies for treating acute rejection episodes in kidney transplant recipients 2017 · Cochrane Headline outcomes only
RR 0.42 [0.17, 1.01]
1 study · 30 participants
Low